Silencing invariant chains of dendritic cells enhances anti-tumor immunity using small-interfering RNA

Chinese Medical Journal

Volumn 123, Issue 22, 2010, Pages 3193-3199

  ke, Shan ^a   Chen, Xue Hua ^b   Zhu, Zheng Gang ^b   Li, Jian Fang ^b   Yu, Bei Qin ^b   Gu, Qin Long ^b   Liu, Bing Ya ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Dendritic cells; Invariant chain; Small interfering RNA; Tumor immunity

Indexed keywords

CHAPERONE; DENDRITIC CELL VACCINE; INVARIANT CHAIN PROTEIN; SMALL INTERFERING RNA; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN SYNTHESIS INHIBITION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; BLOTTING, WESTERN; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; GENE SILENCING; HISTOCOMPATIBILITY ANTIGENS CLASS II; MICE; NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 78651249549     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.22.004     Document Type: Article

References (38)

1. Adema GJ. Dendritic cells from bench to bedside and back. Immunol Lett 2009; 122: 128-130.
2. Srivastava RM, Khar A. Dendritic cells and their receptors in antitumor immune response. Curr Mol Med 2009; 9: 708-724.
3. Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR, et al. Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol 2004; 5: 1143-1148.
4. Cho Y, Miyamoto M, Kato K, Fukunaga A, Shichinohe T, Kawarada Y, et al. CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 2003; 63: 1555-1559.
5. Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 2001; 22: 269-276.
6. Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW, et al. Tumor-specific CD4+ T cells have a major post-licensing role in CTL mediated anti-tumor immunity. J Immunol 2000; 165: 6047-6055.
7. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998; 10: 588-594.
8. Bonehill A, Heirman C, Tuyaerts S, Michiels A, Breckpot K, Brasseur F, et al. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 2004; 172: 6649-6657.
9. You Z, Hester J, Rollins L, Spagnoli GC, van der Bruggen P, Chen SY. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses. Cancer Res 2001; 61: 197-205.
10. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998; 188: 2199-2204.
11. Yewdell JW, Norbury CC, Bennink JR. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv Immunol 1999; 73: 1-77.
12. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A 1995; 92: 11671-11675.
13. Pieters J. MHC class II-restricted antigen processing and presentation. Adv Immunol 2000; 75: 159-208.
14. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811.
15. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000; 101: 25-33.
16. Yang D, Lu H, Erickson JW. Evidence that processed small dsRNAs may mediate sequence-specific mRNA degradation during RNAi in Drosophila embryos. Curr Biol 2000; 10: 1191-1200.
17. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000; 404: 293-296.
18. Olsen PH, Ambros V. The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Dev Biol 1999; 216: 671-680.
19. Mochizuki K, Fine NA, Fujisawa T, Gorovsky MA. Analysis of a piwi-related gene implicates small RNAs in genome rearrangement in tetrahymena. Cell 2002; 110: 689-699.
20. Zhao Y, Boczkowski D, Nair SK, Gilboa E. Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T-cell responses and tumor immunity. Blood 2003; 102: 4137-4142.
21. Ke S, Chen XH, Li H, Li JF, Gu QL, Liu BY, et al. Silencing invariant chain of DCs enhances Th1 response using small interfering RNA. Cell Biol Int 2007; 31: 663-671
22. Son YI, Egawa S, Tatsumi T, Redlinger RE, Jr, Kalinski P, Kanto T. A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells. J Immunol Methods 2002; 262: 145-157.
23. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393: 478-480.
24. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393: 474-478.
25. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 480-483.
26. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999; 189: 753-756.
27. Bakke O, Dobberstein B. MHC class II-associated invariant chain contains a sorting signal for endosomal compartments. Cell 1990; 63: 707-716.
28. Lamb CA, Yewdell JW, Bennink JR, Cresswell P. Invariant chain targets HLA class II molecules to acidic endosomes containing internalized influenza virus. Proc Natl Acad Sci U S A 1991; 88: 5998-6002.
29. Anderson MS, Miller J. Invariant chain can function as a chaperone protein for class II major histocompatibility complex molecules. Proc Natl Acad Sci U S A 1992; 89: 2282-2286.
30. Qiu G, Goodchild J, Humphreys RE, Xu M. Cancer immunotherapy by antisense suppression of Ii protein in MHC-class-II-positive tumor cells. Cancer Immunol Immunother 1999; 48: 499-506.
31. Martinez J, Patkaniowska A, Urlaub H, Luhrmann R, Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002; 110: 563-574.
32. Hannon GJ. RNA interference. Nature 2002; 418: 244-251.
33. Hill JA, Ichim TE, Kusznieruk KP, Li M, Huang X, Yan X, et al. Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol 2003; 171: 691-696.
34. Ribas A. Genetically modified dendritic cells for cancer immunotherapy. Curr Gene Ther 2005; 5: 619-628.
35. Liu BY, Chen XH, Gu QL, Li JF, Yin HR, Zhu ZG, et al. Antitumor effects of vaccine consisting of dendritic cells pulsed with tumor RNA from gastric cancer. World J Gastroenterol 2004; 10: 630-633.
36. Zhang HM, Zhang LW, Liu WC, Cheng J, Si XM, Ren J. Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma. Cytotherapy 2006; 8: 580-588.
37. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184: 465-472.
38. Grunebach F, Muller MR, Nencioni A, Brossart P. Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther 2003; 10: 367-374.